Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.
India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.
Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.
Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's…
India’s Mercury Laboratories intends to boost its exports but an EMA report shows regulators aren't impressed with what the company is doing now.
The deal follows a flurry of consumer deals and comes as J&J's beauty products have been delivering strong growth, thanks in part to Ci:z.
China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.
The FDA, which banned products from a South Korean sterile manufacturer last spring, has now followed up with a warning letter.
The punishment, an amount rarely seen in China, includes confiscation of illegal gains and a fine three times those sales.
India’s Dr. Reddy’s Laboratories says it will unload an API manufacturing plant to the Middle East-based Neopharma.